Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Indian J Pharmacol
; 53(3): 226-228, 2021.
Article
in English
| MEDLINE | ID: covidwho-1282691
ABSTRACT
Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin 1 Receptor Antagonist Protein
/
Antibodies, Neutralizing
/
Antibodies, Monoclonal, Humanized
/
Janus Kinase Inhibitors
/
Cytokine Release Syndrome
/
COVID-19 Drug Treatment
/
Antibodies, Monoclonal
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Indian J Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
Ijp.IJP_615_20
Similar
MEDLINE
...
LILACS
LIS